Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90.

[1]  S. Hennessy,et al.  Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer. , 2022, Clinical lung cancer.

[2]  R. Hubbard,et al.  Very high PD‐L1 expression as a prognostic indicator of overall survival among patients with advanced non‐small cell lung cancer receiving anti‐PD‐(L)1 monotherapies in routine practice , 2022, Pharmacoepidemiology and drug safety.

[3]  T. Lv,et al.  Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis , 2022, British journal of cancer.

[4]  Eun Jeong Min,et al.  Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid Cancers. , 2021, JAMA oncology.

[5]  Mingfeng He,et al.  First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis , 2021, Cancer Immunology, Immunotherapy.

[6]  G. Giaccone,et al.  Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer. , 2021, Journal of Thoracic Oncology.

[7]  Anala Gossai,et al.  Validation analysis of a composite real‐world mortality endpoint for patients with cancer in the United States , 2021, Health services research.

[8]  A. Tafreshi,et al.  Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Mok,et al.  FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC , 2021 .

[10]  G. Yancopoulos,et al.  Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial , 2021, The Lancet.

[11]  K. Syrigos,et al.  First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  D. Carbone,et al.  First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[13]  R. Pathak,et al.  Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials , 2020, Cancer.

[14]  G. Giaccone,et al.  Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. , 2020, The New England journal of medicine.

[15]  P. Conte,et al.  Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer. , 2020, Cancer treatment reviews.

[16]  S. Digumarthy,et al.  Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[18]  David Bourque,et al.  Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database , 2019, JAMA.

[19]  S. Khozin,et al.  Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer , 2019, bioRxiv.

[20]  D. Planchard,et al.  Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy , 2018, JAMA oncology.

[21]  M. Provencio,et al.  Hyperprogression as a distinct outcome after immunotherapy. , 2018, Cancer treatment reviews.

[22]  R. Herbst,et al.  Should chemotherapy plus immune checkpoint inhibition be the standard front‐line therapy for patients with metastatic non–small cell lung cancer? , 2018, Cancer.

[23]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[24]  A. Abernethy,et al.  Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting , 2018, JAMA.

[25]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[26]  S. Murgu,et al.  Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy. , 2018, Journal of thoracic disease.

[27]  A. Abernethy,et al.  Use of Electronic Health Record Data for Quality Reporting. , 2017, Journal of oncology practice.

[28]  M. Socinski,et al.  First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[29]  Y. Shentu,et al.  Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. , 2017 .

[30]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[31]  Amy P Abernethy,et al.  Opportunities and challenges in leveraging electronic health record data in oncology. , 2016, Future oncology.

[32]  A. Liede,et al.  Validation of International Classification of Diseases coding for bone metastases in electronic health records using technology-enabled abstraction , 2015, Clinical epidemiology.

[33]  E. Stuart,et al.  Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.

[34]  Douglas G Altman,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.

[35]  Douglas G Altman,et al.  Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines , 2009, BMC medical research methodology.

[36]  M. Kenward,et al.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls , 2009, BMJ : British Medical Journal.

[37]  Peter C Austin,et al.  The performance of different propensity score methods for estimating marginal hazard ratios , 2007, Statistics in medicine.

[38]  Theo Stijnen,et al.  Using the outcome for imputation of missing predictor values was preferred. , 2006, Journal of clinical epidemiology.

[39]  P. Royston,et al.  Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects , 2002, Statistics in medicine.

[40]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[41]  H. Kim,et al.  Balance diagnostics after propensity score matching. , 2019, Annals of translational medicine.